Graham Jackson, MD, PhD

home / authors / graham-jackson-md-phd

Articles

Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

Graham Jackson, MD, PhD
March 24th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Read More

Dr. Jackson on the Toxicity Profile of Lenalidomide Maintenance in Myeloma

Dr. Jackson on the Toxicity Profile of Lenalidomide Maintenance in Myeloma

Graham Jackson, MD, PhD
February 9th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the toxicity profile of lenalidomide maintenance therapy in the treatment of patients with multiple myeloma.

Read More

Dr. Jackson on Benefits of Maintenance Therapy for Myeloma

Dr. Jackson on Benefits of Maintenance Therapy for Myeloma

Graham Jackson, MD, PhD
January 18th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the benefits of maintenance therapy for patients with multiple myeloma.

Read More

Dr. Jackson on Lenalidomide as a Highly-Effective Maintenance Therapy in Myeloma

Dr. Jackson on Lenalidomide as a Highly-Effective Maintenance Therapy in Myeloma

Graham Jackson, MD, PhD
December 7th 2016

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need